Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evoq RemediesBOM:543500 +2.92%58 PB Ratio is 0.10 as of Aug. 25, 2026, which is 81% below its 10-year median of 0.53. GuruFocus rates BOM:543500 with a GF Score™ of 58/100 and a GF Value™ of ₹12.86 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 112 Medical Distribution companies, Evoq Remedies ranks better than 98.21% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-25), Evoq Remedies's share price is ₹1.76. Evoq Remedies's Book Value per Share for the quarter that ended in Mar. 2026 was ₹17.79. Hence, Evoq Remedies's PB Ratio of today is 0.10.
Good Sign:
Evoq Remedies Ltd stock PB Ratio (=0.1) is close to 5-year low of 0.1.
The historical rank and industry rank for Evoq Remedies's PB Ratio or its related term are showing as below:
BOM:543500'
s PB Ratio Range Over the Past 10 Years
Min: 0.1 Med: 0.53 Max: 1.28
Current: 0.1
During the past 8 years, Evoq Remedies's highest PB Ratio was 1.28. The lowest was 0.10. And the median was 0.53.
BOM:543500's PB Ratio is ranked better than 98.21% of 112
companies
in the Medical Distribution industry
Industry Median: 1.075
vs BOM:543500: 0.10
During the past 12 months, Evoq Remedies's average Book Value Per Share Growth Rate was -0.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 65.30% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Evoq Remedies was 923.50% per year. The lowest was -0.80% per year. And the median was 223.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Evoq Remedies PB Ratio Related Terms
Evoq Remedies PB Ratio Historical Data
* Premium members only.
The historical data trend for Evoq Remedies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Evoq Remedies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evoq Remedies PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Evoq Remedies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Evoq Remedies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Evoq Remedies's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Evoq Remedies (BOM:543500) has a PB Ratio of 0.10 as of Aug. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Evoq Remedies and its competitors. This is 81% below median its historical median of 0.53. Over the past decade, Evoq Remedies' PB Ratio has ranged from 0.10 to 1.28. According to the industry distribution chart, Evoq Remedies ranks #2 out of 112 companies in the Medical Distribution industry, placing it in the top 1.8%.
Is Evoq Remedies' PB Ratio too high?
Evoq Remedies' current PB Ratio of 0.10 is 81% below median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.28. The Medical Distribution industry median PB Ratio is 1.08. Evoq Remedies' value of 0.10 is 90.7% below this industry median. Based on the distribution chart, Evoq Remedies ranks #2 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Evoq Remedies has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evoq Remedies' PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Evoq Remedies ranks #2 out of 112 companies for PB Ratio. This places Evoq Remedies in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.08. Evoq Remedies' value of 0.10 is 90.7% below this benchmark. Historically, Evoq Remedies' own PB Ratio has ranged from 0.10 to 1.28 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 1.08, Evoq Remedies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.08, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evoq Remedies's current PB Ratio of 0.10 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Evoq Remedies and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evoq Remedies's current PB Ratio is 0.10, which is 81% below median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evoq Remedies stock overvalued right now?
Based on GuruFocus' analysis, Evoq Remedies (BOM:543500) is currently considered Possible Value Trap. The stock's GF Value™ is ₹12.86, compared to a current price of ₹1.76 — trading 86.3% below its estimated fair value. The current PB Ratio is 0.10, which is 81% below median its 10-year median of 0.53 and 90.7% below the Medical Distribution industry median of 1.08. Evoq Remedies' overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Evoq Remedies (BOM:543500), the current PB Ratio is 0.10 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evoq Remedies (BOM:543500) Overvalued in 2026?
Based on GuruFocus' analysis, Evoq Remedies stock appears to be undervalued.
The current stock price of ₹1.76 is trading 86.3% below its estimated GF Value™ of ₹12.86.
GuruFocus considers Evoq Remedies to be Possible Value Trap.
Key valuation signals for BOM:543500:
PB Ratio: 0.10 (81% below median its 10-year median of 0.53)
GF Value™: ₹12.86 vs. price of ₹1.76 (86.3% below fair value)
Industry Position: 90.7% below the Medical Distribution median (#2 of 112)
No single metric tells the full story. See the BOM:543500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading, and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections, and others. It operates in a single segment that is Pharmaceutical Trading.
58GF Score
Get the complete analysis for BOM:543500
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543500 has been successfully added to your 
